Evaluating fecal microbiota transplantation for ulcerative colitis treatment
Official title: A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis
Run by The University of Texas Health Science Center, Houston · NCT05786404 · Data updated 2026-11-12
This study is testing if a new treatment using fecal microbiota transplantation can help people with active ulcerative colitis feel better.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Drugs / interventions | chemotherapy, prednisone |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | December 15, 2023 |
| Main results expected | December 15, 2026 |
| Study ends | December 15, 2027 |
| Registry record updated | May 10, 2024 |
| Trial ID | NCT05786404 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with active ulcerative colitis who meet specific clinical criteria.
✕Probably not a fit
Patients with severe ulcerative colitis or those unable to take retention enemas or capsules may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the safety, feasibility, and preliminary efficacy of fecal microbiota transplantation (FMT) in patients with active ulcerative colitis (UC). Participants will receive either frozen FMT via retention enema or lyophilized powder in oral capsules as an induction treatment. The study will also analyze changes in the microbiome, including diversity and specific genera, as well as the proportion of antibody-coated microbiota from baseline to post-treatment. The goal is to determine the effectiveness of microbiota replacement therapy in managing active UC.
Why it matters
Potential benefit: If successful, this treatment could provide a novel therapeutic option for patients suffering from active ulcerative colitis.
How similar studies have gone: Other studies have shown promise in using fecal microbiota transplantation for gastrointestinal conditions, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of active UC defined on clinical grounds (Partial Mayo score ≥ 3 with each subscore \>1) * Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the study. * Female subjects of childbearing potential must have a negative urine Qualitative Human Chorionic Gonadotropin(HCG)pregnancy test at enrolment and on the Week 1, Day 1 of the Treatment prior to administration of study drug. * Willing and able to sign an informed consent form and attend all study-related clinic visits, assessments, and follow-up phone calls. * Subject has an attending physician who will provide the non-FMT care. Exclusion Criteria: * Subjects with sever UC (Mayo score of \>7) * Unable to take retention enema or multiple capsules orally. * Females who are pregnant, breastfeeding, or planning to become pregnant during the study. * Receipt of systemic non-topical antibiotics within 14 days of treatment day 1. * Positive results for active HIV, Hepatitis B, or Hepatitis C infections. * History of recurrent Clostridium difficile infection or FMT in the past 6-months. * History of other active gastrointestinal conditions such as irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis etc. * Known history of bile acid diarrhea * Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone \>20 mg a day or prednisone-equivalent) * History of active cancer and/or ongoing chemotherapy (superficial non-metastatic cancers and maintenance chemotherapy are permitted). * History of use of an investigational drug within 90 days prior to the screening visit. * History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives. * Life expectancy of \< 1 year. * In the opinion of investigator, subject for any reason, should be excluded from the study. * Absolute neutrophil count (ANC) \< 500IU/mL
Where it's running
-
The University of Texas Health Science Center at Houston
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Herbert L DuPont, MD — The University of Texas Health Science Center, Houston
- Study coordinator: Herbert L DuPont, MD
- Email: herbert.l.dupont@uth.tmc.edu
- Phone: 713 500 6687
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Circadian Variation of Anti-Factor Xa in Trauma Patients on LMWH
This study tests whether anti-Factor Xa levels show a daily rhythm in hospitalized trauma patients receiving LMWH for VTE prevention.
-
PrioritiesAI: A chat tool to help older adults with hernia decide what matters most for surgery
This study tests an AI-powered chat assistant to help people with hernia clearly express and communicate their health goals for elective surgery.
-
Family-based program to reduce risk factors for schizophrenia spectrum disorders in youth with family history
This study tests a brief family-based psychosocial program to see if it lowers persistent psychotic-like experiences in kids and young adults with a family history of SSD and different brain risk patterns.
-
EUS-Guided RFA for Pancreatic Lesions: Safety and Outcomes
This study tests whether using endoscopic ultrasound-guided radiofrequency ablation is safe and helps patients with pancreatic lesions.
-
Skin-to-skin care with the Skincubator for preterm infants
This study tests whether using the Skincubator during skin-to-skin care is safe and feasible for preterm babies and their parents in the NICU.
-
See if iCHAMPSS 2.0 helps schools spread effective sexual health programs
This study tests whether iCHAMPSS 2.0 helps Texas schools implement an evidence-based sexual health program more effectively for teachers, administrators, and health staff.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.